NeuroQuest
Immuno-based Blood Tests for Early Detection of Alzheimer's Disease
StartupNeuroQuest is a startup in the Health Tech & Life Sciences sector, established in 2008. Immuno-based Blood Tests for Early Detection of Alzheimer's Disease. The company has raised a total of $1.75M across 3 funding rounds, currently at the A stage. Key investors include South Carolina Research Authority, The Trendlines Group, The InterTech Group. The company has 1-10 employees. Core technologies: Biologicals.
With $1.75M in total funding, NeuroQuest is a A-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageA
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQMisgav Regional Council, Tchelet Street 17, Israel
- Last Round$750K
- South Carolina Research Authority
- The Trendlines Group
- The InterTech Group
4 articles covered by sources including www.biospace.com,
alz-journals.onlinelibrary.wiley.com,
www.charlestondigitalcorridor.com,
nocamels.com.
What does NeuroQuest do?
NeuroQuest has developed NeuroScreen™, a novel blood-based diagnostic test for Alzheimer's disease (AD). The technology is based on the specific response of the immune system to a amyloid-beta accumulation. The company's propriety technology is based on the award-winning research of Professor Michal Schwartz of the Weizmann Institute of Science. NeuroQuest has licensed the intellectual property covering this technology from Yeda (the Technology Transfer Company of the Weizmann Institute of Science) and holds an exclusive global license for its development and commercialization. NeuroQuest has established a US subsidiary and clinical development center in Charleston, South Carolina with the assistance and financial support of the South Carolina Research Authority (SCRA). They are working with Vikor Scientific, a CLIA-certified lab, to provide the data required for FDA approval, and with Pentara Corporation for data analysis.
How much funding has NeuroQuest raised?
NeuroQuest has raised $1.75M in total funding across 3 rounds. The company is currently at the A stage. Key investors include South Carolina Research Authority, The Trendlines Group, The InterTech Group.
What sector is NeuroQuest in?
NeuroQuest operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Providers, Laboratories, Consumers, Demographics & Family, Seniors.
Where is NeuroQuest located?
NeuroQuest is based in Misgav Regional Council, Tchelet Street 17, Israel. The company also has offices abroad.